Moss 9 July, 2026
Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic tests, today announced its results for the second quarter of 2026.
Highlights include:
-
Record sales of NOK 49.8 million in Q2 2026, up 14% (20% currency neutral organic growth). Revenue of NOK 93.7 million in H1 2026, up 6% (12% currency neutral organic growth).
-
EBITDA of NOK 8.1 million in Q2 2026 vs NOK 1.7 million in Q2 2025. 1H 2026 EBITDA of NOK 13.1 million versus NOK 15.7 million in 1H 2025. Pipeline investments expensed over the P&L amounted to NOK 6.6 million Q2 2026 vs NOK 4.1 million in Q2 2025.
-
Gross margin of 55% (44% in Q2’25). The gross margin for 1H 2026 was 54%, unchanged from 1H 2025.
-
The Bühlmann collaboration delivers overall very strong performance. fCAL turbo sales increased by 35% in Q2 2026 compared to Q2 2025 with new accounts added and good performance across all regions. Continued positive outlook for growth in upcoming quarters.
-
Sales to the US were NOK 10.4 million in Q2 2026 vs NOK 7.2 million in Q2 2025 with good Cystatin C performance, reflecting a 45% growth vs Q2 2025.
-
The company has implemented an updated R&D strategy and new pipeline governance to support disciplined prioritisation of R&D resources and capital allocation. Current R&D spending will be maintained targeting a return on capital employed of more than 20% on new projects.
-
Collaboration with Essange Reagents announced in June will further expand pipeline opportunities for Gentian.
GDASA Q2 26 presentation
GDASA Q2 2026 report
Webcast
The company will present the results today at 09.00 am, followed by a Q&A session. The presentation will be held as a live webcast on the company's website: https://www.gentian.com/investor-relation/presentations
The webcast will also be available on the company website after the presentation.
IR contact:
Njaal Kind,
CFO
njaal.kind@gentian.no
+47 919 06 525 (mobile)
About Gentian Diagnostics
Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in vitro diagnostic reagents. Our mission is to innovate diagnostic efficiency for better treatment decisions. Gentian’s expertise and focus lie within immunoassays, specifically for infections, inflammation, kidney disease and heart failure. By converting existing and clinically relevant biomarkers to the most efficient, high-throughput analysers, the company contributes to saving costs and protecting life. Gentian Diagnostics is headquartered in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA, and China. For more information, please visit www.gentian.com.
This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 in the Norwegian Securities Trading Act. This stock exchange announcement was published by Njaal Kind, Chief Financial Officer at Gentian Diagnostics ASA, on 9 July 2026 at 07:30 CET.